Skip to main content

Table 2 Proportion of women’s correct responses on the questions of the core principles of predictive epigenetic testing for breast, ovarian, cervical, and endometrial cancer risk

From: Women’s perception, attitudes, and intended behavior towards predictive epigenetic risk testing for female cancers in 5 European countries: a cross-sectional online survey

  Percentage of correct responders (95%CI)
Correct items of the surveyed core principles of predictive epigenetic testing for female cancer risks All Countries
N = 1675
Czech Republic
n = 356
Germany
n = 335
United Kingdom
n = 323
Italy
n = 338
Sweden
n = 323
p-value*
The predictive epigenetic test for female cancer risks targets a woman’s risk for breast, ovarian, cervical, and endometrial cancer. 94.6 (93.4, 95.6) 93.5 (90.5, 95.9) 98.5 (96.6, 99.5) 96.0 (93.2, 97.8) 89.1 (85.2, 92.2) 96.0 (93.2, 97.8) <.001
With a lower-than-average risk result, a woman could consider having less screening and consequently may reduce her likelihood of overdiagnosis and false alarms. 57.4 (55.0, 59.8) 43.0 (37.8, 48.3) 57.0 (51.5, 62.4) 81.1 (76.4, 85.2) 62.1 (56.7, 67.3) 44.9 (39.5, 50.5) <.001
With a higher-than-average risk result, a woman could consider having more screening or preventive measure in order to reduce her likelihood of dying from cancer. 76.2 (74.1, 78.2) 47.5 (42.2, 52.8) 83.9 (79.5, 87.7) 87.6 (83.5, 91.0) 76.3 (71.4, 80.8) 88.2 (84.2, 91.5) <.001
Our environment and lifestyle is changing the epigenome of our cells. 75.3 (73.2, 77.4) 66.3 (61.1, 71.2) 79.1 (74.4, 83.3) 87.3 (83.2, 90.7) 72.8 (67.7, 77.5) 72.1 (66.9, 77.0) <.001
  1. *p-values derived from Chi-Square analysis